AMPH logo

AMPH
Amphastar Pharmaceuticals Inc

1,134
Mkt Cap
$850.99M
Volume
849,067.00
52W High
$31.26
52W Low
$16.65
PE Ratio
11.32
AMPH Fundamentals
Price
$18.85
Prev Close
$19.30
Open
$19.28
50D MA
$20.21
Beta
0.80
Avg. Volume
434,136.33
EPS (Annual)
$2.03
P/B
1.09
Rev/Employee
$364,315.28
$1,661.95
Loading...
Loading...
News
all
press releases
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
News Placeholder
More News
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given a consensus rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and tw...
MarketBeat
News Placeholder
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
AMPH vs. RDY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
News Placeholder
Amphastar Pharmaceuticals (AMPH) to Release Earnings on Wednesday
Amphastar Pharmaceuticals (NASDAQ:AMPH) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-amphastar-pharmaceuticals-inc-stock...
MarketBeat
News Placeholder
Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Boston Trust Walden Corp lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,087,266 shares...
MarketBeat
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Down 7.4% - Time to Sell?
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Down 7.4% - Should You Sell...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available